CLINICAL
TRIAL OF SOOKTYN
AN AYURVEDIC FORMULATION
IN THE TREATMENT OF HYPERACIDITY
By
S. W.
TRIVEDI
HEAD OF GASTRO-ENTEROLOGY SURGERY DEPT.
CIVIL HOSPITAL & B. J. MEDICAL COLLEGE,
AHMEDABAD GUJARAT
INTRODUCTION
Heart-burn, acid
eructation, epigastric pain and discomfort are the most common symptoms of
Hyper-acidity Syndrome. Hyper-acidity requires prompt and effective treatment
as otherwise this may gradually progress to the formation of duodenal gastric
ulcer. Sardesai (1), R Ngabhashyam (2) and Venugopalan (3) have all reported
the beneficial effects of Sooktyn in the management of Hyper-acidity syndrome
and have stated that this drug is devoid of side effects generally seen with the
conventional antacids. With this back-ground, we planned to undertake a
clinical trial of Sooktyn in the treatment of Hyper-acidity syndrome.
SOOKTYN
Composition :
Each tablet of Sooktyn contains in mg
SooktyBhasma (Ostrea Gryphoides) -
112.5 mg
Kapurkachali (Hedychium spicatum) - 80.0 mg
Jatamansi (Nardostachyajatamansi) - 40.0 mg
Ganthoda (Valerianawallichii) - 30.0 mg
KhurasaniAjmo
(Hyocyamusniger) - 30.0 mg
Kel pan raakh
(Musa sapientum — salt) - 30.0 mg
Vacha (Acorus calamus) - 10.0 mg
Dhaturana pan (Datura Stramonium) - 5.0 mg
PROPERTIES OF SOOKTYN
This has
anti-inflammatory, antacid, antispasmodic, anti-allergic, digestive, demulcent
and detoxicating properties.
PATIENTS AND METHODS .
This clinical
trial was undertaken on patients attending the O.P.D. of Gastroenterology
Surgical Unit of the Civil Hospital, Ahmedabad, during the year 1983. Only
those with hyperacidity were enrolled. Those patients having duodenal or
gastric ulcer were excluded from the study. Patients having any systemic disease
were also excluded from the study.
Sixty patients were included in the study. However out of them only 48 patients
could be followed-up in full and so the results of only these were analyzed.
They were asked to report once in 15 days for check-up and also to receivethe
drug. They were told to come earlier in case they found it necessary
Patients were
advised Sooktyn 2 tabs three or four times a day. In severe cases they were
advised to take 3-4 tabs three or four times a day. The dosage was modified, if
necessary, at each check-up of 15 days and those showing satisfactory
improvement were advised to take 2 tabs two or three times a day. All the
patientswere treated continuously for three months, though some of them had
complete relief even before that. No other drug or pain killer was used during
the course of Sooktyn trial.
FOLLOW-UP
All the patients
were followed-up for six months to observe for any relapse or recurrence of
symptoms.